We consistently found a high degree of synergism when combining idasanutlin with the BH3-mimetic ABT-263 in p53wt cell lines and obtained similar results with venetoclax, a specific BCL2 inhibitor not targeting BCL-XL to safeguard against on-target thrombocytopenia. This evidence concerns the gene BCL2L1 and Thrombocytopenia.